STERIS DEF 14A Details Executive Equity Compensation

TL;DR

**STERIS's executive pay is heavily weighted towards equity, signaling a long-term focus that should reassure investors.**

AI Summary

STERIS plc's DEF 14A filing, dated June 12, 2025, primarily details executive compensation for the fiscal years ending March 31, 2021, 2022, 2023, and 2024, rather than providing a comprehensive financial overview of revenue or net income. The document focuses on equity awards, including stock and option awards, granted to named executive officers like Walter M. Rosebrough Jr. and Daniel J. Carestio. For instance, the filing tracks changes in the fair value of outstanding and unvested equity awards, as well as dividends or other earnings paid on equity awards. While specific dollar amounts for total compensation are not explicitly summarized for all executives across all years in the provided snippet, the detailed breakdown of equity components indicates a significant portion of executive remuneration is tied to long-term performance incentives. The strategic outlook and key business changes are not detailed in this specific excerpt, which is typical for a DEF 14A focused on proxy matters.

Why It Matters

This DEF 14A filing is crucial for investors as it sheds light on how STERIS plc aligns executive incentives with shareholder value through equity compensation. Understanding the structure of stock and option awards for key executives like Walter M. Rosebrough Jr. and Daniel J. Carestio can indicate management's long-term commitment and potential for future performance. For employees, it provides transparency into the compensation philosophy at the highest levels, potentially influencing morale and retention. In a competitive market for medical device and sterilization services, executive compensation practices can also signal a company's ability to attract and retain top talent, impacting its competitive edge against rivals like Getinge or Cantel Medical.

Risk Assessment

Risk Level: low — The risk level is low because this DEF 14A filing primarily concerns executive compensation disclosures, which are standard regulatory requirements and do not inherently introduce new operational or financial risks. The document details equity awards and their fair value changes for named executives, providing transparency rather than indicating new vulnerabilities. There are no mentions of significant litigation, regulatory non-compliance, or adverse financial events.

Analyst Insight

Investors should review the full DEF 14A to understand the complete executive compensation packages and performance metrics tied to equity awards. This information can inform their proxy voting decisions and provide insight into the board's governance practices and alignment with shareholder interests.

Executive Compensation

Key Numbers

• 2025-06-12 — Filing Date (Date the DEF 14A was filed)
• 2025-07-31 — Conformed Period of Report (Period to which the filing relates)
• 001-38848 — SEC File Number (Unique identifier for STERIS's SEC filings)
• 0001757898 — Central Index Key (CIK) (Unique identifier for STERIS plc)

Key Players & Entities

• STERIS plc (company) — filer of DEF 14A
• Walter M. Rosebrough Jr. (person) — named executive officer
• Daniel J. Carestio (person) — named executive officer
• SEC (regulator) — recipient of filing
• Bloomberg (company) — publisher of analysis

FAQ

Industry Context

STERIS plc operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry (SIC 3842). This sector is characterized by innovation in medical devices, stringent regulatory oversight, and a competitive landscape driven by technological advancements and healthcare spending trends.

Regulatory Implications

As a medical device company, STERIS is subject to rigorous regulatory scrutiny from bodies like the FDA and international equivalents. Compliance with evolving regulations regarding product safety, manufacturing processes, and market approvals is critical and can impact operational costs and market access.

What Investors Should Do

1. Review executive compensation details
2. Monitor changes in equity award valuations

Key Dates

• 2025-06-12: Filing Date — Indicates when the DEF 14A proxy statement was submitted to the SEC.
• 2025-07-31: Conformed Period of Report — Specifies the period to which the information in the filing pertains, typically the end of the fiscal year.
• 2018-11-01: Former Company Name Change — Marks the date STERIS Ltd changed its name to STERIS plc.

Glossary

DEF 14A

A proxy statement filed by public companies with the SEC detailing information about the annual meeting of shareholders, including executive compensation, board of directors, and voting matters. (This document is the primary source of information regarding executive compensation and related corporate governance matters for STERIS plc.)

Central Index Key (CIK)

A unique identifier assigned to each entity that files with the SEC. (0001757898 is STERIS plc's unique identifier for SEC filings.)

SEC File Number

A unique identifier assigned by the SEC to a company's filings. (001-38848 is STERIS plc's SEC file number.)

Equity Awards

Forms of compensation granted to employees, typically executives, that are tied to the company's stock, such as stock options or restricted stock units. (A significant portion of STERIS's executive compensation is structured around these awards, indicating a focus on long-term performance incentives.)

Fair Value of Equity Awards

The estimated market value of stock options or other equity awards at a specific point in time, often used for accounting and compensation reporting. (The filing tracks changes in the fair value of outstanding and unvested equity awards, providing insight into the potential value of executive compensation.)

Year-Over-Year Comparison

This DEF 14A filing focuses on executive compensation for fiscal years ending March 31, 2021, through 2024. It details equity awards, stock options, and changes in their fair value for named executive officers. Unlike a 10-K, it does not provide a comprehensive overview of revenue, net income, or other financial performance metrics compared to the previous year's filing. Therefore, a direct comparison of key financial metrics is not possible based on this excerpt.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 12, 2025 by Walter M. Rosebrough Jr. regarding STERIS plc (STE).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR